Jinghuaweikang capsules combined with furazolidone-based triple or quadruple therapy as the rescue treatment for Helicobacter pylori infection: a multicenter randomized controlled clinical trial

• Published in: Zhong hua yi xue za zhi Vol. 96; no. 40; p. 3206
• Main Authors: Cheng, H, Hu, F L, Sheng, J Q, An, H J, Xu, L, Liu, F X, Li, Y, Hao, Q, Zheng, P Y, Lu, G F, Cao, Z Q, Wang, Y P
• Format: Journal Article
• Language: Chinese
• Published: China 01.11.2016
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Capsules; Drug Therapy, Combination; Eructation; Furazolidone; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies
• ISSN: 0376-2491
• DOI: 10.3760/cma.j.issn.0376-2491.2016.40.002

To explore the efficacy of Jinhuaweikang capsules plus furazolidone-based triple or quadruple therapy as the rescue treatment for ( . ) infection. This is a prospective randomized controlled multicenter clinical trial. Patients with chronic gastritis from . infection in whom eradication treatment failed were recruited from 6 hospitals. All patients were divided into 4 groups using stratified randomization: group A1 (PAFJ), receiving pantoprazole 40 mg+ amoxicillin 1 000 mg+ furazolidone 100 mg+ Jinghuaweikang 3 capsules, twice a day for 10 d (d1-10); group A2, PAFJ therapy as in group A1, followed by Jinghuaweikang 3 capsules twice a day for 18 d (d11-28); group B1 (PAFB), receiving pantoprazole 40 mg+ amoxicillin 1 000 mg+ furazolidone 100 mg+ bismuth potassium citrate 220 mg, twice a day for 10 d (d1-10); group B2, PAFB therapy as in group B1, followed by Jinghuaweikang 3 capsules twice a day for 18 d (d11-28). At least 28 days after the end of treatment, all patients underwent C urea breath test for assess